
dEEGtal Insight secures CHF 1 million to transform epilepsy diagnosis
16 December 2024

Geneva-based Medtech dEEGtal Insight has raised over CHF 1 million in seed funding to advance its AI-powered epilepsy diagnostic software. With substantial support from the Wyss Center, this innovative solution aims to enhance diagnostic accuracy and improve outcomes for millions of patients worldwide.
dEEGtal Insight has secured over CHF 1 million in seed funding to propel its AI-driven epilepsy diagnostic tool toward clinical validation and market readiness. The funding includes CHF 750,000 from the Wyss Center in Geneva, a leading institution in medical technology innovation.
Epilepsy affects millions globally, with 10 million people experiencing a potential first seizure annually. However, current diagnostic tools often lack the sensitivity needed to detect subtle markers of epilepsy. Up to 80% of initial EEG readings appear normal, delaying diagnosis and leaving untreated patients at a 70% risk of relapse. dEEGtal Insight addresses these challenges with an AI-powered solution designed to enhance diagnostic precision and enable earlier interventions.
The software utilizes artificial intelligence trained on extensive EEG datasets to identify subtle markers often missed during visual analysis. It generates a comprehensive risk score even in the absence of visible indicators, offering clinicians deeper insights for more accurate diagnoses. The system is designed for seamless integration into clinical workflows, with features such as automated reporting and a user-friendly interface.
A growing market opportunity
The CHF 1 million seed funding will be used to refine AI models, conduct clinical validation studies, and prepare for regulatory approval. dEEGtal aims to secure FDA clearance for the U.S. market, followed by CE marking for Europe and Switzerland. The start-up plans to introduce its solution in leading neurology centers in the United States before expanding internationally.
With the global epilepsy diagnostics market projected to grow from CHF 3.3 billion in 2024 to over CHF 10 billion by 2032, dEEGtal Insight is well-positioned to capture significant market share. Its innovative technology not only improves epilepsy diagnosis but also holds potential for applications in other neurological conditions, offering a promising outlook for the future.